ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urothelial Carcinoma of the Renal Pelvis and Ureter
Mirati Therapeutics Inc.antibody_drug_conjugatePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Urothelial Carcinoma of the Renal Pelvis and Ureter cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Cardiff University | Phase 3 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II Nagoya University | Phase 3 | BBB |
VINBLASTINE University of Southern California | Phase 3 | BBB |
Inno-206 University of Southern California | Phase 3 | BBB |
FILGRASTIM Tulane University Health Sciences Center | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →